During the 2017 ACR/ARHP Annual Meeting, advances in biosimilar treatments were abuzz. However, many speakers noted that the presence of biosimilars on the market has not yet resulted in greater access to treatment and lower drug pricing in the U.S…


Larry Beresford |
During the 2017 ACR/ARHP Annual Meeting, advances in biosimilar treatments were abuzz. However, many speakers noted that the presence of biosimilars on the market has not yet resulted in greater access to treatment and lower drug pricing in the U.S…

What initially strikes people about Christopher Adams, MD, FACP, FACR, is his passion for fairness. In 2015, he told readers of The Rheumatologist, “Patients often feel powerless to fight the system and advocate for themselves, and many of my patients felt they lacked a mechanism for addressing their concerns. That’s where we come in.” Dr….

When former ACR President Joseph Flood, MD, tapped Deborah Dyett Desir, MD, to volunteer for an ACR committee, he might have assumed that her preference would be to serve on the Committee on Rheumatologic Care or its Insurance Subcommittee. After all, Dr. Desir is in private practice at the Arthritis and Osteoporosis Center PC in…
Together our voice is heard; our influence is alive. In 2017, ACR members heard the call of the Rheumatology Strong campaign and joined the American Medical Association (AMA) in force, ensuring the College maintains its representation in the country’s largest—and arguably most influential—physician society. “We surpassed our minimum 1,000-member goal by a margin and are hopeful…

Nan Yang, PharmD, & Kurt Oelke, MD, on behalf of the ARHP Practice Committee |
Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting in San Diego last month, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the ACR winners about their individual contributions to advancing rheumatology. In coming issues, we…
Lisa Rapaport |
(Reuters Health)—When one person in a household gets prescribed opioids, the other people who live with them are more likely to get their own prescriptions for these narcotic painkillers, a U.S. study suggests. Researchers examined data on about 12.6 million people living in a household where someone was prescribed opioids and 6.4 million individuals in…
SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…
Cheryl Platzman Weinstock |
(Reuters Health)—When the fees paid to healthcare providers by Medicaid go up, appointments with primary care doctors suddenly become more available to Medicaid beneficiaries – and the opposite happens when fees go down, according to a recent U.S. study. Researchers found that, overall, every $10 change up or down in the Medicaid fees paid to…
Reuters Staff |
NEW YORK (Reuters)— Consumer sign-ups for Obamacare individual insurance plans were more than 600,000 during the first week of enrollment for 2018, a U.S. health agency said on Thursday, a positive sign for insurers who take part in the healthcare program that Republicans are trying to undo. The Centers for Medicare & Medicaid Services, a…